Cytek Biosciences (NASDAQ:CTKB) Issues Quarterly Earnings Results

Cytek Biosciences (NASDAQ:CTKB) issued its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02, FiscalAI reports. Cytek Biosciences had a negative return on equity of 12.40% and a negative net margin of 38.98%. The business had revenue of $53.23 million during the quarter, compared to the consensus estimate of $53.05 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Revenue growth was modest and uneven: Q3 revenue rose 2% to $53.2 million, with U.S. revenue up 12% and academic and government sales up 38%; APAC revenue fell 25% year over year, while biopharma, CRO and distributor revenue declined 17%.
• High-end instrument demand was a bright spot. Combined Aurora and Aurora Evo placements increased 23%, with Evo placements nearly doubling; high-end Full Spectrum Profiling instrument revenue grew 11%.
• Gross margin improved, but adjusted EBITDA declined. Gross margin expanded nearly 600 basis points to 59%, helped by lower manufacturing overhead, material costs and tariffs; adjusted EBITDA was $0.7 million versus $2.5 million a year earlier, reflecting higher operating expenses and lower investment income.
• Cytek maintained its full-year revenue outlook and narrowed its 2026 guidance to $208 million–$211 million. Management expects Q4 revenue to rise meaningfully with seasonal purchasing and projects adjusted EBITDA around break-even for the year.
• Patent litigation remains unresolved, but management says operations are unaffected. A jury found infringement under the doctrine of equivalents on one claim, and Cytek is seeking to overturn the verdict; the company said it can continue selling and shipping products and expects litigation expenses to decrease in Q4.

Cytek Biosciences Stock Down 1.3%

NASDAQ:CTKB traded down $0.08 on Wednesday, reaching $5.88. The company’s stock had a trading volume of 1,567,839 shares, compared to its average volume of 1,373,870. Cytek Biosciences has a 12-month low of $3.31 and a 12-month high of $6.34. The stock has a 50 day moving average price of $5.35 and a 200 day moving average price of $4.67. The firm has a market cap of $764.28 million, a price-to-earnings ratio of -9.48 and a beta of 1.15.

Wall Street Analyst Weigh In

CTKB has been the subject of a number of analyst reports. Stephens reissued an “overweight” rating and issued a $6.00 price objective on shares of Cytek Biosciences in a report on Friday, October 23rd. Morgan Stanley set a $5.00 target price on shares of Cytek Biosciences in a research note on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Monday, September 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cytek Biosciences has an average rating of “Hold” and a consensus price target of $5.88.

About Cytek Biosciences

Cytek Biosciences, Inc develops and commercializes cell analysis solutions for biomedical research, clinical research and biopharmaceutical applications. The company focuses on spectral flow cytometry, a technology that enables researchers to analyze multiple characteristics of individual cells and identify complex cell populations.

Its product portfolio includes the Aurora and Northern Lights spectral flow cytometers, compact and specialized instruments, cell sorters, software and a range of fluorescent reagents.